Eledon Pharmaceuticals, Inc.
ELDNHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. Valued at $186.9M, ELDN is a micro-cap name in its sector. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Market Cap
$186.9M
Beta
0.85
P/E (TTM)
—
P/E (Fwd)
-2.99
EPS (TTM)
$-0.90
EPS (Fwd)
$-0.77
ROE
-110.7%
ROA
-39.0%
Cash
$88.8M
Total Debt
$467,000
Free CF
-$45.1M
52W Change
-40.0%
Annual Financials
Cash vs Debt
Where ELDN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ELDN finished 35.71% below its 150-day moving average ($3.36) and 29.64% below its 200-day moving average ($3.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELDN overbought or oversold?
At the October 20, 2026 close, ELDN's RSI(14) was 27.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $88.8M in cash comfortably exceeding the $467K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$45.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -110.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Eledon Pharmaceuticals, Inc. and its sector.